Oncaspar
pegaspargase
Table of contents
Overview
Oncaspar is a cancer medicine used in adults and children to treat acute lymphoblastic leukaemia (ALL), a cancer of white blood cells called lymphoblasts. Oncaspar is used in combination with other cancer medicines.
It contains the active substance pegaspargase.
-
List item
Oncaspar : EPAR - Medicine overview (PDF/77.2 KB)
Adopted
First published: 29/01/2016
Last updated: 10/01/2019 -
-
List item
Oncaspar : EPAR - Risk-management-plan summary (PDF/256.94 KB)
First published: 29/01/2016
Last updated: 15/04/2021
Authorisation details
Product details | |
---|---|
Name |
Oncaspar
|
Agency product number |
EMEA/H/C/003789
|
Active substance |
pegaspargase
|
International non-proprietary name (INN) or common name |
pegaspargase
|
Therapeutic area (MeSH) |
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
Anatomical therapeutic chemical (ATC) code |
L01XX24
|
Publication details | |
---|---|
Marketing-authorisation holder |
Les Laboratoires Servier
|
Revision |
16
|
Date of issue of marketing authorisation valid throughout the European Union |
14/01/2016
|
Contact address |
Les Laboratoires Servier |
Product information
13/09/2022 Oncaspar - EMEA/H/C/003789 - II/0048
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.